tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

INSM Stock Latest News

Insmed’s Growth Potential: Buy Rating Backed by TPIP’s Market Promise and Strong Sales Projections
RatingsInsmed’s Growth Potential: Buy Rating Backed by TPIP’s Market Promise and Strong Sales Projections
2d ago
INSM
Insmed participates in a conference call with Cantor Fitzgerald
PremiumThe Fly
Insmed participates in a conference call with Cantor Fitzgerald
8d ago
INSM
Insmed’s Promising Pipeline and Market Potential Drive Buy Rating
PremiumRatings
Insmed’s Promising Pipeline and Market Potential Drive Buy Rating
12d ago
INSM
Insmed price target raised to $96 from $92 at BofA
PremiumThe Fly
Insmed price target raised to $96 from $92 at BofA
26d ago
INSM
United Therapeutics price target lowered to $314 from $328 at BofA
PremiumThe Fly
United Therapeutics price target lowered to $314 from $328 at BofA
27d ago
INSM
LQDA
Innovative Gene Therapy Approach Drives Buy Rating for Insmed in DMD Treatment
PremiumRatingsInnovative Gene Therapy Approach Drives Buy Rating for Insmed in DMD Treatment
28d ago
INSM
Insmed assumed with an Overweight at Morgan Stanley
Premium
The Fly
Insmed assumed with an Overweight at Morgan Stanley
1M ago
INSM
Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating
Premium
Ratings
Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating
1M ago
INSM
Insmed price target raised to $110 from $105 at UBS
PremiumThe Fly
Insmed price target raised to $110 from $105 at UBS
1M ago
INSM
Block upgraded, Domino’s downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Block upgraded, Domino’s downgraded: Wall Street’s top analyst calls
2M ago
AB
YY
RBC Capital starts Insmed at Outperform on brensocatib launch momentum
PremiumThe Fly
RBC Capital starts Insmed at Outperform on brensocatib launch momentum
2M ago
INSM
Insmed initiated with an Outperform at RBC Capital
PremiumThe Fly
Insmed initiated with an Outperform at RBC Capital
2M ago
INSM
Insmed’s Brensocatib Receives FDA Priority Review
PremiumCompany AnnouncementsInsmed’s Brensocatib Receives FDA Priority Review
2M ago
8K
INSM
Insmed: FDA won’t hold advisory meeting to discuss NDA for brensocatib
Premium
The Fly
Insmed: FDA won’t hold advisory meeting to discuss NDA for brensocatib
2M ago
INSM
Insmed’s Earnings Call Highlights Record Growth and Strategic Moves
Premium
Company Announcements
Insmed’s Earnings Call Highlights Record Growth and Strategic Moves
2M ago
INSM
Insmed price target raised to $108 from $105 at Truist
PremiumThe Fly
Insmed price target raised to $108 from $105 at Truist
2M ago
INSM
Insmed price target lowered to $96 from $97 at Stifel
PremiumThe Fly
Insmed price target lowered to $96 from $97 at Stifel
2M ago
INSM
Insmed’s Strategic Growth Potential and Market Opportunities Justify Buy Rating
PremiumRatings
Insmed’s Strategic Growth Potential and Market Opportunities Justify Buy Rating
2M ago
INSM
Insmed’s Strong 2024 Growth and Promising Pipeline
PremiumCompany Announcements
Insmed’s Strong 2024 Growth and Promising Pipeline
2M ago
INSM
Ritu Baral’s Buy Rating for Insmed Supported by Strong Financials and Promising Pipeline
PremiumRatingsRitu Baral’s Buy Rating for Insmed Supported by Strong Financials and Promising Pipeline
2M ago
INSM
Insmed Board Member Alfred Altomari to Step Down
Premium
Company Announcements
Insmed Board Member Alfred Altomari to Step Down
2M ago
8K
INSM
Insmed reports Q4 EPS ($1.32), consensus ($1.16)
Premium
The Fly
Insmed reports Q4 EPS ($1.32), consensus ($1.16)
2M ago
INSM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >